Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SU014813 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| SU014813 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SU014813 | DRUG | 100 mg capsule/day for 6 cycle of 21 days |
Inclusion Criteria: * Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent. * Must have received prior treatment with an anthracycline and a taxane either concurrently or se...
SU014813 is an investigational small molecule being studied for the treatment of breast cancer and other solid tumors. In clinical trials, it has been evaluated in patients with metastatic breast cancer and in patients with advanced solid malignancies. It is being developed by Pfizer, Inc. and is currently in Phase 2 clinical development.
SU014813 is a small molecule developed by Pfizer, Inc. for oncology indications. Its specific molecular target has not been disclosed in the available information. The drug is being studied in patients with breast cancer and other solid tumors, but its mechanism of action is not publicly detailed.
SU014813 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in Phase 2 clinical development for the treatment of breast cancer and other solid tumors.
SU014813 is in Phase 2 clinical development. It has completed a Phase 2 trial in patients with metastatic breast cancer and a Phase 1 trial in patients with advanced solid malignancies. The drug is not approved by regulatory authorities and remains investigational.
SU014813 has been studied in two completed clinical trials. NCT00322517 was a Phase 2 study in patients with metastatic breast cancer, enrolling 90 female participants across the United States, Germany, Italy, Netherlands, and the United Kingdom. NCT00982267 was a Phase 1 trial in patients with advanced solid tumors, enrolling 77 participants in Germany and the Netherlands.
Yes, SU014813 is also known as SU14813. Both names refer to the same investigational drug developed by Pfizer, Inc. The Phase 1 trial NCT00982267 uses the name SU14813, while the Phase 2 trial NCT00322517 uses SU-014813. Both trials study the same compound in oncology indications.